Figure 1: Subject Disposition

457 screened

279 randomized

278 in Intent to Treat, Exposed Population

178 subjects did not randomize

1 subject did not consume drug

138 randomized to ABC/3TC/ZDV

140 randomized to ATV+3TC/ZDV

35 (25%) prematurely discontinued
- 6 (4%) adverse events
- 12 (9%) lost to follow-up
- 2 (1%) consent withdrawn
- 9 (7%) virologic failure
- 6 (4%) other reasons

41 (29%) prematurely discontinued
- 11 (8%) adverse events
- 14 (10%) lost to follow-up
- 1 (<1%) consent withdrawn
- 10 (11%) virologic failure
- 3 (2%) investigator decision
- 2 (2%) protocol violation

Study completion status was missing for 1 subject

103 (74%) completed Week 48

98 (70%) completed Week 48